

Pubmed (from January 1, 1990 to February 23, 2020)

((("melanoma"[Mesh]) OR (melanoma*[Title/Abstract]) OR (malignant melanoma*[Title/Abstract]) OR (melanoma*, malignant[Title/Abstract])) AND ((("mucous membrane"[Mesh]) OR (mucous membrane*[Title/Abstract]) OR (mucosa*[Title/Abstract]) OR (membrane*, mucous[Title/Abstract])) OR (mucosal melanoma[Title/Abstract])) AND (("Antibodies" [MeSH Terms]) OR (immune*[Title/Abstract]) OR (CTLA-4[Title/Abstract]) OR (CTLA4[Title/Abstract]) OR (cytotoxic T-lymphocyte-associated[Title/Abstract]) OR (ipilimumab[Title/Abstract]) OR (yervoy[Title/Abstract]) OR (programmed cell death protein[Title/Abstract]) OR (PD-1[Title/Abstract]) OR (PDCD1[Title/Abstract]) OR (pembrolizumab[Title/Abstract]) OR (keytruda[Title/Abstract]) OR (nivolumab[Title/Abstract]) OR (opdivo[Title/Abstract]) OR (toripalimab [Title/Abstract]) OR (JS001[Title/Abstract]) OR (cemiplimab[Title/Abstract]) OR (libtayo[Title/Abstract]) OR (PD-L1[Title/Abstract]) OR (CD274[Title/Abstract]) OR (atezolizumab[Title/Abstract]) OR (tecentriq[Title/Abstract]) OR (durvalumab[Title/Abstract]) OR (imfinzi[Title/Abstract]) OR (avelumab[Title/Abstract]) OR (bavencio[Title/Abstract])))

Embase (from January 1, 1990 to February 23, 2020)

- #1 'mucosal melanoma'/exp
- #2 'mucosal melanoma*':ab,kw,ti
- #3 'mucosal neoplasm*':ab,kw,ti
- #4 #1 or #2 or #3
- #5 'antibody'/exp
- #6 'immune*':ab,kw,ti
- #7 CTLA-4:ab,kw,ti
- #8 CTLA4:ab,kw,ti
- #9 'cytotoxic T-lymphocyte-associated':ab,kw,ti
- #10 ipilimumab:ab,kw,ti
- #11 yervoy:ab,kw,ti

#12 'programmed cell death protein':ab,kw,ti
#13 PD-1:ab,kw,ti
#14 PDCD1:ab,kw,ti
#15 pembrolizumab:ab,kw,ti
#16 keytruda:ab,kw,ti
#17 nivolumab:ab,kw,ti
#18 opdivo:ab,kw,ti
#19 toripalimab:ab,kw,ti
#20 JS001:ab,kw,ti
#21 cemiplimab:ab,kw,ti
#22 libtayo:ab,kw,ti
#23 PD-L1:ab,kw,ti
#24 CD274:ab,kw,ti
#25 atezolizumab:ab,kw,ti
#26 tecentriq:ab,kw,ti
#27 durvalumab:ab,kw,ti
#28 imfinzi:ab,kw,ti
#29 avelumab:ab,kw,ti
#30 bavencio:ab,kw,ti
#31 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
OR #26 OR #27 OR #28 OR #29 OR #30
#32 #4 AND #31

Cochrane library (from January 1, 1990 to February 23, 2020)

#1 MeSH descriptor: [Melanoma] explode all trees
#2 Melanoma*:ti,ab,kw (Word variations have been searched)
#3 Malignant Melanoma*:ti,ab,kw (Word variations have been searched)
#4 #1 OR #2 OR #3
#5 MeSH descriptor: [Mucous Membrane] explode all trees

- #6 Mucous Membrane*:ti,ab,kw (Word variations have been searched)
- #7 Mucosal Tissue*:ti,ab,kw (Word variations have been searched)
- #8 Mucosa*:ti,ab,kw (Word variations have been searched)
- #9 #5 OR #6 OR #7 OR #8
- #10 Mucosal Melanoma*:ti,ab,kw (Word variations have been searched)
- #11 (#4 AND #9) OR #10
- #12 MeSH descriptor: [Antibodies] explode all trees
- #13 immune*:ti,ab,kw (Word variations have been searched)
- #14 CTLA-4:ti,ab,kw (Word variations have been searched)
- #15 CTLA4:ti,ab,kw (Word variations have been searched)
- #16 cytotoxic T-lymphocyte-associated:ti,ab,kw (Word variations have been searched)
- #17 ipilimumab:ti,ab,kw (Word variations have been searched)
- #18 yervoy:ti,ab,kw (Word variations have been searched)
- #19 programmed cell death protein:ti,ab,kw (Word variations have been searched)
- #20 PD1:ti,ab,kw (Word variations have been searched)
- #21 PD-1:ti,ab,kw (Word variations have been searched)
- #22 PDCD1:ti,ab,kw (Word variations have been searched)
- #23 pembrolizumab:ti,ab,kw (Word variations have been searched)
- #24 keytruda:ti,ab,kw (Word variations have been searched)
- #25 nivolumab:ti,ab,kw (Word variations have been searched)
- #26 opdivo:ti,ab,kw (Word variations have been searched)
- #27 toripalimab:ti,ab,kw (Word variations have been searched)
- #28 JS001:ti,ab,kw (Word variations have been searched)
- #29 cemiplimab:ti,ab,kw (Word variations have been searched)
- #30 libtayo:ti,ab,kw (Word variations have been searched)
- #31 PD-L1:ti,ab,kw (Word variations have been searched)
- #32 CD274:ti,ab,kw (Word variations have been searched)
- #33 atezolizumab:ti,ab,kw (Word variations have been searched)
- #34 tecentriq:ti,ab,kw (Word variations have been searched)
- #35 durvalumab:ti,ab,kw (Word variations have been searched)

#36 imfinzi:ti,ab,kw (Word variations have been searched)

#37 avelumab:ti,ab,kw (Word variations have been searched)

#38 bavencio:ti,ab,kw (Word variations have been searched)

#39 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38

#40 #11 AND #39

Web of Science (from January 1, 1990 to February 23, 2020)

TS=((mucosal melanoma*) AND ((immune*) OR (CTLA-4) OR (CTLA4) OR
(cytotoxic T-lymphocyte-associated) OR (ipilimumab) OR (yervoy) OR (programmed
cell death protein) OR (PD-1) OR (PDCD1) OR (pembrolizumab) OR (keytruda) OR
(nivolumab) OR (opdivo) OR (toripalimab) OR (JS001) OR (cemiplimab) OR (libtayo)
OR (PD-L1) OR (CD274) OR (atezolizumab) OR (tecentriq) OR (durvalumab) OR
(imfinzi) OR (avelumab) OR (bavencio)))

Trial register (updated: February 2020)

Search term: mucosal melanoma

ISRCTN registry (www.controlled-trials.com)

US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov)

Australian New Zealand Clinical Trials Registry (www.anzctr.org.au)

World Health Organization International Clinical Trials Registry Platform
(www.who.int/trialsearch)

EU Clinical Trials Register (<https://www.clinicaltrialsregister.eu>)

Chinese Clinical Trial Registry (<http://www.chictr.org.cn>)

Conference abstracts (January 2014 - February 2020)

Search term: mucosal melanoma

American Society of Clinical Oncology (ASCO)

Society of Melanoma Research (SMR)

European Society of Medical Oncology (ESMO)

European Association of Dermato-Oncology (EADO)